M.A. Aitkhozhin Institute of Molecular Biology and Biochemistry, 86 Dosmukhamedov St., Almaty 050012, Kazakhstan; Almaty Branch of the National Center for Biotechnology, 14 Zhahanger St., Almaty 050054, Kazakhstan.
M.A. Aitkhozhin Institute of Molecular Biology and Biochemistry, 86 Dosmukhamedov St., Almaty 050012, Kazakhstan; Almaty Branch of the National Center for Biotechnology, 14 Zhahanger St., Almaty 050054, Kazakhstan.
Clin Immunol. 2022 May;238:109024. doi: 10.1016/j.clim.2022.109024. Epub 2022 Apr 27.
Coronavirus disease 2019 (COVID-19) is a potentially life-threatening infection characterized by excessive inflammation, coagulation disorders and organ damage. A dysregulated myeloid cell compartment is one of the most striking immunopathologic signatures of this newly emerged infection. A growing number of studies are reporting on the expansion of myeloid cells with immunoregulatory activities in the periphery and airways of COVID-19 patients. These cells share phenotypic and functional similarities with myeloid-derived suppressor cells (MDSCs), which were first described in cancer patients. MDSCs are a heterogeneous population of pathologically activated myeloid cells that exert immunosuppressive activities against mainly effector T cells. The increased frequency of these cells in COVID-19 patients suggests that they are involved in immune regulation during this infection. In this article, we review the current findings on MDSCs in COVID-19 and discuss the complex role of these cells in the immunopathology of COVID-19.
新型冠状病毒病 2019（COVID-19）是一种潜在的危及生命的感染，其特征是过度炎症、凝血障碍和器官损伤。髓系细胞区室失调是这种新出现的感染最显著的免疫病理特征之一。越来越多的研究报告称，COVID-19 患者的外周血和气道中存在具有免疫调节活性的髓系细胞扩增。这些细胞与髓系来源的抑制细胞（MDSCs）具有表型和功能相似性，MDSCs 最初在癌症患者中被描述。MDSCs 是一群异质性的病理性激活的髓系细胞，对主要效应 T 细胞发挥免疫抑制作用。COVID-19 患者中这些细胞的频率增加表明它们参与了感染期间的免疫调节。在本文中，我们回顾了 COVID-19 中 MDSCs 的最新发现，并讨论了这些细胞在 COVID-19 免疫病理学中的复杂作用。
